Philip Jacobs1, Douglas Lier2, Katherine Gooch3, Katharina Buesch4, Michelle Lorimer5, Ian Mitchell6. 1. Department of Medicine, University of Alberta, Edmonton, Alberta; 2. Institute of Health Economics, Edmonton, Alberta; 3. Abbott Laboratories, Abbott Park, Illinois, USA; 4. Abbott Scandinavia AB, Solna, Sweden; 5. Lorimer Enterprises Inc, Alberta Children's Hospital, Calgary, Alberta; 6. Department of Paediatrics, Alberta Children's Hospital, Calgary, Alberta.
Abstract
BACKGROUND: Approximately one in 10 hospitalized patients will acquire a nosocomial infection (NI) after admission to hospital, of which 71% are due to respiratory viruses, including the respiratory syncytial virus (RSV). NIs are concerning and lead to prolonged hospitalizations. The economics of NIs are typically described in generalized terms and specific cost data are lacking. OBJECTIVE: To develop an evidence-based model for predicting the risk and cost of nosocomial RSV infection in pediatric settings. METHODS: A model was developed, from a Canadian perspective, to capture all costs related to an RSV infection hospitalization, including the risk and cost of an NI, diagnostic testing and infection control. All data inputs were derived from published literature. Deterministic sensitivity analyses were performed to evaluate the uncertainty associated with the estimates and to explore the impact of changes to key variables. A probabilistic sensitivity analysis was performed to estimate a confidence interval for the overall cost estimate. RESULTS: The estimated cost of nosocomial RSV infection adds approximately 30.5% to the hospitalization costs for the treatment of community-acquired severe RSV infection. The net benefits of the prevention activities were estimated to be equivalent to 9% of the total RSV-related costs. Changes in the estimated hospital infection transmission rates did not have a significant impact on the base-case estimate. CONCLUSIONS: The risk and cost of nosocomial RSV infection contributes to the overall burden of RSV. The present model, which was developed to estimate this burden, can be adapted to other countries with different disease epidemiology, costs and hospital infection transmission rates.
BACKGROUND: Approximately one in 10 hospitalized patients will acquire a nosocomial infection (NI) after admission to hospital, of which 71% are due to respiratory viruses, including the respiratory syncytial virus (RSV). NIs are concerning and lead to prolonged hospitalizations. The economics of NIs are typically described in generalized terms and specific cost data are lacking. OBJECTIVE: To develop an evidence-based model for predicting the risk and cost of nosocomial RSV infection in pediatric settings. METHODS: A model was developed, from a Canadian perspective, to capture all costs related to an RSV infection hospitalization, including the risk and cost of an NI, diagnostic testing and infection control. All data inputs were derived from published literature. Deterministic sensitivity analyses were performed to evaluate the uncertainty associated with the estimates and to explore the impact of changes to key variables. A probabilistic sensitivity analysis was performed to estimate a confidence interval for the overall cost estimate. RESULTS: The estimated cost of nosocomial RSV infection adds approximately 30.5% to the hospitalization costs for the treatment of community-acquired severe RSV infection. The net benefits of the prevention activities were estimated to be equivalent to 9% of the total RSV-related costs. Changes in the estimated hospital infection transmission rates did not have a significant impact on the base-case estimate. CONCLUSIONS: The risk and cost of nosocomial RSV infection contributes to the overall burden of RSV. The present model, which was developed to estimate this burden, can be adapted to other countries with different disease epidemiology, costs and hospital infection transmission rates.
Authors: Lisa A Grohskopf; Ronda L Sinkowitz-Cochran; Denise O Garrett; Annette H Sohn; Gail L Levine; Jane D Siegel; Beth H Stover; William R Jarvis Journal: J Pediatr Date: 2002-04 Impact factor: 4.406
Authors: J M Langley; J C LeBlanc; E E Wang; B J Law; N E MacDonald; I Mitchell; D Stephens; J McDonald; F D Boucher; S Dobson Journal: Pediatrics Date: 1997-12 Impact factor: 7.124
Authors: Brian A Kuzik; Samim A Al-Qadhi; Steven Kent; Michael P Flavin; Wilma Hopman; Simon Hotte; Sarah Gander Journal: J Pediatr Date: 2007-06-29 Impact factor: 4.406
Authors: Krista L Lanctôt; Shababa T Masoud; Bosco A Paes; Jean-Eric Tarride; Aaron Chiu; Charles Hui; Philip L Francis; Paul I Oh Journal: Curr Med Res Opin Date: 2008-10-16 Impact factor: 2.580
Authors: Arne Simon; Andreas Müller; Karun Khurana; Steffen Engelhart; Martin Exner; Oliver Schildgen; Anna M Eis-Hübinger; Wolfgang Kamin; Thomas Schaible; Karoline Wadas; Roland A Ammann; Anja Wilkesmann Journal: Int J Hyg Environ Health Date: 2007-09-14 Impact factor: 5.840